Paper Information

Journal:   GOVARESH JOURNAL   WINTER 2010 , Volume 14 , Number 4 (69); Page(s) 275 To 278.
 
Paper:  COMPARISON OF FECAL CALPROTECTIN LEVEL IN INFLAMMATORY BOWEL DISEASE AND IRRITABLE BOWEL SYNDROME
 
Author(s):  MEHRJARDI A., SABER AFSHARIAN M.*, MIRSKANDARI M., EBRAHIMI DARYANI N., IRANIKHAH T.
 
* DEPARTMENT OF PATHOLOGY, RASULE AKRAM HOSPITAL, IRAN UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, IRAN
 
Abstract: 

Background: Fecal calprotectin (FC) has been suggested as a noninvasive substitute marker to determine the degree of intestinal inflammation in patients with inflammatory bowel disease (IBD). The aim of this study was to compare FC levels in IBD and irritable bowel syndrome (IBS), to show its discriminative value and relationship with clinical disease activity in patients with IBD.
Materials and Methods: During the time period between May 2008 and November 2009, 41 patients with newly diagnosed or relapse of IBD and 40 patients with IBS who referred to Gastroenterology Clinic of Firoozgar Hospital, Tehran, Iran, were selected in a consecutive random manner. A sample of stool was collected from each patient before colonoscopy, and fecal calprotectin levels were measured using an ELISA kit (Buhlmann Co., Switzerland). Differences in FC levels were considered statistically significant where p<0.05.
Results: Mean calprotectin level in IBD cases (newly diagnosed and relapse) was 193.57±147.79
mg/gr, which was significantly higher than those in IBS cases (28.25±15.13mg/gr) and the difference was statistically significant (p<0.001).
Conclusion: FC levels can be used to differentiate patients with IBD from those with non-inflammatory gastrointestinal disorders such as IBS and can be used as a screening tool for selection of patients who need colonoscopy.

 
Keyword(s): CALPROTECTIN, INFLAMMATORY BOWEL DISEASE, IRRITABLE BOWEL SYNDROME
 
References: 
  • ندارد
 
  Yearly Visit 130
 
Latest on Blog
Enter SID Blog